NCT03341936View on ClinicalTrials.gov

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

July 6, 2021

Study Completion Date

July 6, 2026

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Nivolumab

Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells

DRUG

Lirilumab

Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER